Recce Pharmaceuticals Ltd is an Australia-based company. The Company is engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the processes utilized by bacteria and viruses to overcome resistance.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 09:33:35 2025-06-24 EDT			5-day change	1st Jan Change
0.2200 ^USD	-56.00%		-.--%	-

05-27	Recce Pharmaceuticals Enters Proposed 10-Year Exclusive Licensing Nonbinding Agreement with Middle Eastern Firm, Shares Rise 10%	MT
05-26	Recce Pharmaceuticals signs Middle East licensing term sheet	RE

Market Cap	139M 97.32M 84.85M 78.59M 73.57M 138M 9.18B 932M 361M 4.52B 365M 357M 15.69B	P/E 2026 *	-6.76x	P/E 2027 *	-4.42x
Enterprise Value	147M 103M 89.84M 83.2M 77.89M 146M 9.72B 987M 383M 4.79B 387M 378M 16.62B	EV / Sales 2026 *	19.1x	EV / Sales 2027 *	19.4x
Free-Float	57.05%	Yield 2026 *	-	Yield 2027 *	-

05-27	Recce Pharmaceuticals Enters Proposed 10-Year Exclusive Licensing Nonbinding Agreement with Middle Eastern Firm, Shares Rise 10%	MT
05-26	Recce Pharmaceuticals signs Middle East licensing term sheet	RE
04-20	Recce Pharmaceuticals Says Indonesian Regulator Completes Routine Regulatory Inspection of Phase Three Clinical Trial Site	MT
03-23	Recce Pharmaceuticals Secures Brazilian Family 4 Patent For Anti-Infectives	MT
02-27	Recce Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended December 31, 2025	CI
02-02	Australian Shares Fall; GrainCorp Sees Sharp Earnings Decline in Fiscal 2026	MT
02-01	Recce Pharmaceuticals enters second U.S. Department of Defense research and development agreement	RE
02-01	Recce Pharmaceuticals Enters Into Research Agreement With US Army Institute of Surgical Research	MT
01-14	Recce Pharmaceuticals Ltd Receives AUD 5.3 Million R&D Rebate	CI
12-16	Recce Pharmaceuticals Receives Up to AU$85 Million in Research, Development Finding; Shares Up 3%	MT
12-15	Recce Pharmaceuticals awarded AusIndustry advanced overseas finding for up to A$85M	RE
12-15	Recce Pharmaceuticals Limited Receives Advanced Overseas Finding up to AUD 85 Million	CI
11-26	Recce Pharmaceuticals Secures Family 4 Patent for Anti-Infectives in Hong Kong, Shares Jump 6%	MT

25-04-23	Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections	AQ
25-04-10	Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders	AQ
25-02-27	Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives	AQ
25-02-19	Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway	AQ
25-01-22	Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections	AQ

Recce Pharmaceuticals Ltd Stock OTC Markets

Stocks

RECEF

AU000000RCE5

Pharmaceuticals

Valuation: Recce Pharmaceuticals Ltd

Chart: Recce Pharmaceuticals Ltd

Latest news : Recce Pharmaceuticals Ltd

Press Releases: Recce Pharmaceuticals Ltd

Quotes and Performance

Course Extremes

Managers and Directors: Recce Pharmaceuticals Ltd

Other Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Annual profits - Rate of surprise

Manager	Title	Age	Since
James Graham CEO	Chief Executive Officer	-	2020-08-27
Justin Reynolds DFI	Director of Finance/CFO	-	-
Michele Dilizia CTO	Chief Tech/Sci/R&D Officer	-	2020-09-29

Director	Title	Age	Since
Michele Dilizia BRD	Director/Board Member	-	2012-09-30
James Graham BRD	Director/Board Member	-	2012-04-30
Alistair McKeough BRD	Director/Board Member	-	2022-08-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RECCE PHARMACEUTICALS LTD	-56.00%	-.--%	-	-	97.32M
ELI LILLY AND COMPANY	-1.21%	-3.04%	+44.03%	+143.07%	980B
JOHNSON & JOHNSON	-2.48%	-5.18%	+52.47%	+39.15%	550B
ABBVIE INC.	-2.14%	-4.94%	+16.83%	+57.08%	382B
ROCHE HOLDING AG	+0.25%	-3.09%	+23.33%	+16.04%	316B
ASTRAZENECA PLC	+0.61%	-1.69%	+27.35%	+13.73%	272B
NOVARTIS AG	+0.22%	-3.10%	+24.67%	+30.49%	268B
NOVO NORDISK A/S	+4.59%	+1.98%	-38.43%	-46.26%	199B
AMGEN INC.	-1.19%	-4.95%	+16.68%	+47.69%	182B
GILEAD SCIENCES, INC.	-1.35%	-1.46%	+14.06%	+59.26%	154B
Average	-5.87%	-3.02%	+20.11%	+40.03%	366.93B
Weighted average by Cap.	-0.78%	-3.68%	+29.49%	+63.31%

	2026 *	2027 *
Net sales	7.68M 5.38M 4.69M 4.35M 4.07M 7.63M 508M 51.55M 19.98M 250M 20.2M 19.77M 868M	8.86M 6.21M 5.42M 5.02M 4.7M 8.81M 586M 59.52M 23.07M 289M 23.32M 22.82M 1B
Net income	-20.45M -14.34M -12.5M -11.58M -10.84M -20.32M -1.35B -137M -53.22M -666M -53.81M -52.66M -2.31B	-30.9M -21.67M -18.89M -17.5M -16.38M -30.72M -2.04B -208M -80.44M -1.01B -81.32M -79.58M -3.49B
Net Debt	8.15M 5.71M 4.98M 4.61M 4.32M 8.1M 539M 54.74M 21.21M 265M 21.45M 20.99M 921M	33.53M 23.51M 20.5M 18.98M 17.77M 33.33M 2.22B 225M 87.28M 1.09B 88.24M 86.35M 3.79B

1 year	0.22	0.22
3 years	0.22	0.6
5 years	0.22	0.6
10 years	0.22	0.6